IBA Hosts the Second Victoria Advisory Committee Meeting to Define the Future of Proton Therapy

Proton therapy

Milan, Italy, April 27, 2019 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announced today that it hosted the second Victoria Advisory Committee meeting, a consortium of worldwide radiation oncology experts to help define the future of Proton Therapy care, in Milan, Italy on April 26.

IBA continues its commitment to develop clinically relevant innovations designed to improve patient outcomes and user experience in partnership with radiation therapy users. Building on the expertise of the largest user community in the industry, IBA delivered the first irradiation of a Spot-Scanning Proton Arc Therapy (SPArc) plan at Beaumont Health Proton therapy Center in Royal Oak Michigan. In March 2019, IBA delivered the first FLASH irradiation at isocenter in an IBA gantry treatment room at the Medical Center Groningen (UMCG) in the Netherlands.

IBA’s Victoria Advisory Committee consists of clinical experts from the world’s leading cancer centers specializing in radiation and proton therapy. This meeting focused on future technology breakthroughs and shaping product roadmaps, as well as accelerating proton therapy adoption through optimized patient selection tools such as Model-Based approaches.

Frederic Genin, Chief Product Officer at IBA,commented: “The second meeting of the Victoria Advisory Committee was very exciting as we conducted an extensive overview of potential game changers in the field of radiation oncology including treatment strategies, novel technologies, artificial intelligence, combined therapy and many others. It is IBA’s aim is to trust the counsel of clinical experts to help ensure that IBA always remains the technology leader in the field of proton therapy”

Hans Langendijk, Professor at University Medical Center Groningen, The Netherlands,added: “The Model-Based approach allows us to not only properly select the patients that will most benefit from proton therapy, but also to assess the clinical benefits of novel technologies such as Proton ARC therapy.”

Peyman Kabolizadeh, MD, PhD, Medical Director, Beaumont Health Proton Therapy Center,added: “I was very happy to report our progress on arc therapy to the committee. The SPArc program is now fully launched and we are very excited about its potential not only in terms of clinical benefits but also regarding patient throughput acceleration where a similar gain is expected as with VMAT.”




About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com


For further information, please contact:

Daniel Ernult
Proton Therapy Marketing Associate
Tel +32 10 201 287